Trichomegaly of the Eyelashes After Lung Cancer Treatment with the Epidermal Growth Factor Receptor Inhibitor Erlotinib-Reference-Cited by-同舟云学术

Trichomegaly of the Eyelashes After Lung Cancer Treatment with the Epidermal Growth Factor Receptor Inhibitor Erlotinib

Published:2008-07-10 Issue:20 Volume:26 Page:3460-3462
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Braiteh Fadi¹,Kurzrock Razelle¹,Johnson Faye M.²

Affiliation:

1. Department of Investigational Cancer Therapeutics, Phase I Program, The University of Texas M.D. Anderson Cancer Center; and The University of Texas Graduate School of Biomedical Sciences Houston, Houston, TX

2. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center; and The University of Texas Graduate School of Biomedical Sciences Houston, Houston, TX

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2008.16.9391

Reference32 articles.

1. Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

2. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

3. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor

4. Congenital Trichomegaly

5. A case of familial trichomegaly in association with oculocutaneous albinism type 1

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lady with long eyelashes…!;International Journal of Trichology;2022

2. Periocular Manifestations of Afatinib Therapy;Ophthalmic Plastic & Reconstructive Surgery;2019-01

3. The Patients’ Journey with Targeted Therapies;Principles of Specialty Nursing;2019

4. A murine model of dry eye induced by topical administration of erlotinib eye drops;International Journal of Molecular Medicine;2017-12-29

5. Pharmacology and Drug Reactions;Dermatology;2017